September 17, 2019 10:29 AM EDT

Amgen inks discovery deal with Hummingbird; Merck gains priority review for Ebola vaccine

ENDPOINTS

→ Amgen has enlisted Hummingbird Bioscience on a new antibody discovery pact, turning over some novel targets to see if the smaller player’s systems …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Amgen inks discovery deal with Hummingbird; Merck gains priority review for Ebola vaccine

ENDPOINTS

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Am­gen inks dis­cov­ery deal with Hum­ming­bird; Mer­ck gains pri­or­i­ty re­view for Ebo­la vac­cine

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Amgen inks discovery deal with Hummingbird; Merck gains priority review for Ebola vaccine